A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/44 (2006.01)
Patent
CA 2169718
The NMDA-antagonistic effect of flupirtine permits the preparation of medicaments for the treatment of cerebral ischemia, neurodegenerative disorders, traumatic brain and bone marrow damage, epileptic attacks and other illnesses.
L'effet antagoniste de la flupirtine vis-à-vis du N-méthyl-D-aspartate permet la préparation de médicaments destinés au traitement des l'ischémie cérébrale, des troubles neurodégénératifs, des lésions traumatiques du cerveau et de la moelle osseuse, des crises d'épilepsie et d'autres maladies.
Engel Jurgen
Nickel Bernd
Pergande Gabriela
Schwarz Michael
Szelenyi Stefan
Asta Medica Aktiengesellschaft
Marks & Clerk
Meda Pharma Gmbh & Co. Kg
LandOfFree
The primary and secondary neuroprotective effect of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with The primary and secondary neuroprotective effect of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The primary and secondary neuroprotective effect of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1452190